Kunal Nepali

查看斯高帕斯 (Scopus) 概要

電子郵件nepalitmu.edutw

h-index

每年研究成果

學歷

2012 Ph.D. ISF College of Pharmacy, Punjab, India
2008 M.S. ISF College of Pharmacy, Punjab, India
2006 B.S. Rajiv Academy For Pharmacy. U.P,, India

經歷

2024.09 - Associate Editor, Journal of Enzyme Inhibition and Medicinal Chemistry (Taylor and Francis, Impact Factor - 5.6)
2023- Associate Professor, Department of Pharmaceutical Sciences, Taipei Medical UniversityTaipei Medical University
2019-2023 Assistant Professor, Department of Pharmaceutical Sciences, Taipei Medical University
2014-2019 Post-Doctoral Research Fellow, Taipei Medical University
2011-2014 Assistant Professor, Guru Nanak Dev University
2008-2011 Assistant Professor, Punjab Technical University

獎項

Editorial Board Member, Medicinal Research Reviews (Wiley, Impact Factor - 10.9).
Editorial board member - Mini Reviews in Medicinal chemistry (IF - 2.91, Chemistry/Medicinal)
Plum Blossom Card (Permanent Resident Certificate) by Government of Taiwan 2020
Outstanding Post Doctoral Fellow (Medicinal Chemistry), 2018, Taipei Medical University, Taiwan.

Project title: The use of organometallic reaction in the synthesis of anticancer agents (2/2)

Outstanding Post Doctoral Fellow (Medicinal Chemistry), 2017, Taipei Medical University, Taiwan.

Project title: The use of organometallic reaction in the synthesis of anticancer agents

Outstanding contribution in reviewing EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017.
Outstanding Post Doctoral Fellow (Medicinal Chemistry), 2016, Taipei Medical University, Taiwan.

Project title: Application of regioselective substitution on 1,4- Benzoquinone derivatives to provide potent anticancer agents

Outstanding contribution in reviewing BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, 2016.
Outstanding Post Doctoral Fellow (Medicinal Chemistry), 2015, Taipei Medical University, Taiwan.

Project title: Preclinical development for novel HSP90 inhibitors as anticancer drugs

Outstanding Post Doctoral Fellow (Medicinal Chemistry), 2015, Taipei Medical University, Taiwan

Project title: Development of ITCHE3 ubiquitin ligase inhibitors as anticancer drug

研究興趣

天然物
有機合成

指紋

查看啟用 Kunal Nepali 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。

1 類似的個人檔案

2 使用中
7 已完成

點擊化學及鈴木偶合反應方法建構鎖定DNA損害修復路徑之小分子雙效抑制劑(1/3)
Nepali, K. (PI)
8/1/24 → 7/31/25
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
點擊化學及鈴木偶合反應方法建構鎖定DNA損害修復路徑之小分子雙效抑制劑
Nepali, K. (PI)
8/1/24 → 7/31/27
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
理性設計全新類型雙效PARP-SYK抑制劑作為抗癌試劑
Nepali, K. (PI)
8/1/23 → 7/31/24
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
Development of a retinoic-base histone deacetylase inhibitor as early-stage AMD treatment
Nepali, K. (PI)
7/1/23 → 2/29/24
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
利用聯芳、生物鹼、黃酮和香豆素的結構工程為特發性肺纖維化提供抗纖維化藥物
Nepali, K. (PI)
8/1/22 → 7/31/23
研究計畫: A - 政府部門 › b - 國家科學及技術委員會

66 文章
28 回顧型文獻
3 書籍
2 章節
更多
- 2 評論/辯論
- 1 前言/後記

Advancing glioblastoma therapy: Learning from the past and innovations for the future
Rana, M., Liou, K. C., Thakur, A., Nepali, K. & Liou, J. P., 5月 1 2025, 於: Cancer Letters. 617, 217601.
研究成果: 雜誌貢獻 › 文章 › 同行評審
Contemporary approaches to mitigating antibacterial drug resistance
Grewal, A. S., Dhingra, A. K., Nepali, K., Deswal, G. & Srivastav, A. L., 4月 1 2024, IGI Global Publishing. 384 p.
研究成果: 書籍/報告 › 書籍
Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress
Sharma, R., Chiang, Y. H., Chen, H. C., Lin, H. Y., Yang, W. B., Nepali, K., Lai, M. J., Chen, K. Y., Liou, J. P. & Hsu, T. I., 4月 1 2024, 於: Cancer Letters. 586, 216666.
研究成果: 雜誌貢獻 › 文章 › 同行評審
5 引文斯高帕斯（Scopus）
Emerging Strategies in Antibacterial Drug Resistance Management: Mechanisms, Challenges, and Novel Interventions
Grewal, A. S., Dhingra, A. K., Nepali, K., Deswal, G. & Srivastav, A. L., 10月 14 2024, Nova Science Publishers, Inc. 297 p.
研究成果: 書籍/報告 › 書籍
First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity In Vitro and In Vivo
Sharma, S., Wang, S. A., Yang, W. B., Lin, H. Y., Lai, M. J., Chen, H. C., Kao, T. Y., Hsu, F. L., Nepali, K., Hsu, T. I. & Liou, J. P., 2月 22 2024, 於: Journal of Medicinal Chemistry. 67, 4, p. 2963-2985 23 p.
研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取
4 引文斯高帕斯（Scopus）

Design, synthesis and evaluation of 2,4-diarylpyrano[3,2-c]chromen-5(4H)-one as a new class of non-purine xanthine oxidase inhibitors
Virdi, H. S. (Creator), Sharma, S. (Contributor), Mehndiratta, S. (Creator), Bedi, P. M. S. (Contributor) & Nepali, K. (Contributor), Figshare, 2015
DOI: 10.6084/m9.figshare.1568378.v1, https://figshare.com/articles/Design_synthesis_and_evaluation_of_2_4_diarylpyrano_3_2_c_chromen_5_4H_one_as_a_new_class_of_non_purine_xanthine_oxidase_inhibitors/1568378/1
資料集: Dataset

Nepali Kunal

個人檔案

學歷

經歷

獎項

研究興趣

指紋

過去五年中的合作和熱門研究領域

深入探索詳細資料

點擊化學及鈴木偶合反應方法建構鎖定DNA損害修復路徑之小分子雙效抑制劑(1/3)

點擊化學及鈴木偶合反應方法建構鎖定DNA損害修復路徑之小分子雙效抑制劑

理性設計全新類型雙效PARP-SYK抑制劑作為抗癌試劑

Development of a retinoic-base histone deacetylase inhibitor as early-stage AMD treatment

利用聯芳、生物鹼、黃酮和香豆素的結構工程為特發性肺纖維化提供抗纖維化藥物

Advancing glioblastoma therapy: Learning from the past and innovations for the future

Contemporary approaches to mitigating antibacterial drug resistance

Dual inhibition of CYP17A1 and HDAC6 by abiraterone-installed hydroxamic acid overcomes temozolomide resistance in glioblastoma through inducing DNA damage and oxidative stress

Emerging Strategies in Antibacterial Drug Resistance Management: Mechanisms, Challenges, and Novel Interventions

First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity In Vitro and In Vivo

Design, synthesis and evaluation of 2,4-diarylpyrano[3,2-c]chromen-5(4H)-one as a new class of non-purine xanthine oxidase inhibitors

Nepali Kunal

個人檔案

學歷

經歷

獎項

研究興趣

指紋

過去五年中的合作和熱門研究領域

專案

研究成果

資料集